Vertex Pharmaceuticals Incorporated
Analysis
Vertex has stopped being a one-disease company. For the first time the newer products are visibly adding growth, and revenue guidance went up again in Q2 FY2026 — but the cost of launching three more businesses lands now, before their sales arrive. How much of the $500 million non-CF target is CASGEVY versus JOURNAVX?
- The growth is no longer coming from cystic fibrosis alone.
CASGEVY and JOURNAVX now drive about a quarter of the company's year-over-year growth, and the full-year revenue target was raised on the back of them. A company that lived on one medicine now has three products paying the bills. How much of that growth is price and currency rather than more patients?
- A real second franchise is already filed and dated.
The kidney drug pove cut proteinuria by 52% in its Phase III interim, and the application is filed with a decision date of November 30. Renal is meant to be Vertex's next big business, and it is a launch now, not a hope.
- The new products cost money well before they earn it.
Marketing spend rose 45% in Q2 FY2026, split between the pain launch and kidney-launch preparation. Management pushed the end of JOURNAVX's free-drug program to the first half of 2027, so the launch keeps costing more than it earns.
- CF switch to once-daily pillVertex keeps its cystic fibrosis franchise growing by moving patients to a once-daily medicine that covers more mutations and reaches younger children.
- Renal launch nears approvalA kidney medicine filed for approval turns a long-discussed pipeline into a near-term launch that management says could one day match cystic fibrosis.
- CASGEVY and JOURNAVX revenueGene therapy and the non-opioid pain drug add revenue outside cystic fibrosis, giving Vertex new growth lines while its core franchise matures.
- Cystic fibrosis concentrationNearly all revenue still comes from cystic fibrosis, and the largest product is shrinking as patients move to the newer once-daily medicine.
- Successor CF pipeline unclearManagement now says beating its own cystic fibrosis drug is very hard, so next-generation candidates may add little and one program was dropped.
- Pain revenue lags prescriptionsJOURNAVX prescriptions are growing quickly, but payer restrictions keep patients on support programs, so revenue lags and the margin fix keeps slipping.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$15K | Jul 23 | Sep 22 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Jun 15 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jun 12 | Aug 22 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Jun 3 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$15K | May 22 | Jul 1 |
Congressional trading data provided by QuiverQuant
How Vertex Pharmaceuticals Incorporated turned $12.0B of revenue into $4.2B of operating income.
| Revenue | ||
|---|---|---|
| TRIKAFTA/KAFTRIO | $10.3B | ▲ 0.72% YoY |
| ALYFTREK | $837.8M | |
| Manufactured Product, Other | $820.1M | ▲ 4.94% YoY |
| Total revenue | $12.0B | |
| Gross profit | $10.3B | 86.2% |
| Operating income | $4.2B | 34.8% |